Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session

Published 14/11/2022, 18:05
Updated 14/11/2022, 19:10
© Reuters.  Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session

Benzinga - Gainers

  • Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.
  • Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares jumped 114.9% to $20.20. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus contingent value rights (CVRs) of up to $8.00 per share.
  • ToughBuilt Industries, Inc. (NASDAQ: TBLT) shares climbed 28.6% to $2.83 after the company reported better-than-expected Q3 EPS results.
  • Cosmos Holdings Inc. (NASDAQ: COSM) rose 27.7% to $0.1569 after gaining 7% on Friday.
  • Yiren Digital Ltd. (NYSE: YRD) jumped 27.7% to $1.29.
  • Exela Technologies, Inc. (NASDAQ: XELA) gained 25.8% to $0.35.
  • Ardelyx, Inc. (NASDAQ: ARDX) surged 25.6% to $1.5700. The FDA published briefing documents on Ardelyx's kidney disease treatment.
  • Ensysce Biosciences, Inc. (NASDAQ: ENSC) jumped 23% to $2.3700 after the company announced it received written guidance from the FDA that an acute pain indication may be appropriate for its lead Trypsin Activated Abuse Protection product, PF614.
  • CIRCOR International, Inc. (NYSE: CIR) surged 20.6% to $26.15 following better-than-expected quarterly results.
  • HireRight Holdings Corporation (NYSE: HRT) gained 19.1% to $9.18. HireRight’s board authorized a $100 million share repurchase program.
  • PDS Biotechnology Corporation (NASDAQ: PDSB) jumped 18.2% to $6.62 after the company announced 100% clinical response in cervical cancer patients in preliminary data from the IMMUNOCERV Phase 2 clinical trial. The company also reported better-than-expected Q3 EPS results.
  • Daseke, Inc. (NASDAQ: DSKE) gained 15.7% to $6.91. Daseke said that the company has entered into an agreement with its Founder, Mr. Don R. Daseke, and his affiliates, to repurchase their total holdings in the company at a purchase price of $6 per share.
  • HUTCHMED (China) Limited (NASDAQ: HCM) rose 15.3% to $11.41 after the company reported positive topline result in Fruquintinib Phase III FRUTIGA study in second-line gastric cancer in China.
  • Armata Pharmaceuticals, Inc. (NYSE: ARMP) jumped 14.6% to $3.29. Armata Pharmaceuticals recently reported a Q3 loss of $0.24 per share.
  • MINISO Group Holding Limited (NYSE: MNSO) gained 14.5% to $8.10 after the company reported better-than-expected Q1 financial results.
  • Helius Medical Technologies, Inc. (NASDAQ: HSDT) gained 14% to $0.2975 following strong quarterly results.
  • Agenus Inc. (NASDAQ: AGEN) rose 13.8% to $2.8550. Agenus recently posted a Q3 loss of $0.19 per share.
  • HUTCHMED (China) Limited (NASDAQ: HCM) surged 13.1% to $11.20 after the company reported initial results from FRUTIGA. The company said the trial met one of the primary endpoints of statistically significant improvement in progression-free survival.
  • Xinyuan Real Estate Co., Ltd. (NYSE: XIN) surged 12.6% to $0.5181.
  • Babcock & Wilcox Enterprises, Inc. (NYSE: BW) gained 10.4% to $5.38. Babcock & Wilcox Construction Co. LLC was awarded $42 million in large North American upgrade projects.
  • Secoo Holding Limited (NASDAQ: SECO) gained 10.3% to $0.32.
  • TAL Education Group (NYSE: TAL) gained 10.1% to $5.24.
  • Kidpik Corp. (NASDAQ: PIK) rose 10.1% to $0.9798. KIDPIK is expected to release Q3 results on November 15, 2022.
  • monday.com Ltd. (NASDAQ: MNDY (NASDAQ:MNDY)) surged 9.2% to $103.94 after the company reported better-than-expected Q3 financial results.
  • Cabaletta Bio, Inc. (NASDAQ: CABA) gained 8.8% to $2.59. Cabaletta Bio recently posted a Q3 loss of $0.39 per share.
Lufax Holding Ltd (NYSE: LU) jumped 6.8% to $1.9550.

Losers

  • Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) shares dipped 83.3% to $0.6781 after the company reported topline results from the STS101 SUMMIT Phase 3 efficacy trial in migraine patients.
  • SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) dipped 39.8% to $2.74 after the company reported Q3 earnings results and provided a business update.
  • POINT Biopharma Global Inc. (NASDAQ: PNT) dropped 33% to $6.12. Lantheus and POINT Biopharma announced collaboration and exclusive license agreements for commercialization of PNT2002 & PNT2003.
  • Nuwellis, Inc. (NASDAQ: NUWE) fell 31.7% to $0.1366. Nuwellis recently reported worse-than-expected Q3 EPS and sales results.
  • MorphoSys AG (NASDAQ: MOR) shares fell 28.8% to $3.91. MorphoSys’ licensing partner Roche issued an update on Phase 3 GRADUATE program for Gantenerumab in early Alzheimer’s disease.
  • Stoke Therapeutics, Inc. (NASDAQ: STOK) dipped 26% to $9.24 after the company reported a wider Q3 loss.
  • Actelis Networks, Inc. (NASDAQ: ASNS) dropped 21.5% to $0.62. Actelis Networks posted a Q3 loss of $0.13 per share.
  • Tremor International Ltd (NASDAQ: TRMR) fell 21.2% to $6.95 after gaining over 5% on Friday.
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) dipped 21% to $0.9401. Infinity Pharmaceuticals posted a Q3 loss of $0.12 per share and issued an update from MARIO-3 study.
  • 908 Devices Inc. (NASDAQ: MASS) declined 19.2% to $12.93 as the company lowered its FY22 revenue forecast.
  • Oatly Group (NASDAQ:OTLY) AB (NASDAQ: OTLY) fell 18.2% to $2.0050 after the company reported worse-than-expected Q3 EPS and sales results.
  • Fast Radius, Inc. (NASDAQ: FSRD) shares fell 17.2% to $0.2015 after dropping around 7% on Friday.
  • Lumos Pharma, Inc. (NASDAQ: LUMO) declined 16.5% to $7.44. Lumos Pharma posted a Q3 loss of $0.86 per share and disclosed interim results from two Phase 2 trials evaluating oral LUM-201 for moderate pediatric growth hormone deficiency.
  • TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) dropped 16.4% to $0.6001. TOMI Environmental Solutions recently posted a Q3 loss of $0.03 per share.
  • Altus Power, Inc. (NYSE: AMPS) dropped 15.2% to $7.24 following Q3 results.
  • Minerva Surgical, Inc. (NASDAQ: UTRS) declined 15.4% to $0.2404.
  • CareMax, Inc. (NASDAQ: CMAX) dipped 14.8% to $4.64. CareMax recently posted a Q3 loss of $0.25 per share.
  • Performance Shipping Inc. (NASDAQ: PSHG) fell 14.4% to $0.2695. Performance Shipping posted Q3 EPS of $0.10.
  • Ascendis Pharma A/S (NASDAQ: ASND) dipped 13.3% to $114.48. Ascendis Pharma announced positive topline results from the ACcomplisH Phase 2 trial of once-weekly TransCon CNP compared to a placebo in children with achondroplasia aged 2 to 10 years old.
  • Algonquin Power & Utilities Corp. (NYSE: AQN) fell 12% to $8.18. Algonquin Power & Utilities Corp reported worse-than-expected Q3 EPS. Several analysts downgraded the stock today.
  • Transphorm, Inc. (NASDAQ: TGAN) fell 11.7% to $6.22.
  • 5E Advanced Materials Inc. (NASDAQ: FEAM) dropped 9.9% to $11.32. 5E Advanced Materials, on Friday, reported Q1 results.
  • CS Disco, Inc. (NYSE: LAW) fell 9.6% to $9.35.
  • Kura Sushi USA, Inc. (NASDAQ: KRUS) fell 9.4% to $59.64. Kura Sushi USA recently reported Q4 financial results.
  • 8x8, Inc. (NYSE: EGHT) fell 9.4% to $4.3050.
  • Qurate Retail, Inc. (NASDAQ: QRTEA) dropped 9.1% to $1.7450.
  • Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 8.9% to $3.5977. Bed Bath & Beyond reported additional privately negotiated senior notes exchanges and concurrent private placement of common stock with several institutional holders.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.